1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsQuantum Leap pharma-led funding program for drug discovery research is sponsored by Quebec Consortium for Drug Discovery (CQDM). This program supports innovative translational biopharmaceutical research projects at advanced stages of development.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
##### Request for proposals: Drug Discovery Research CQDM - Biopharmarceutical Research Consortium Brain Canada &Quebec Consortium for Drug Discovery (CQDM) is pleased to share an upcoming funding opportunity for Canadian researchers.
CQDM’s Quantum Leap pharma-led funding program for drug discovery research aims to support innovative translational biopharmaceutical research projects that are at advanced stages of development and that have the potential to improve, facilitate and/or accelerate the drug discovery process and the development of safer and more effective drugs.
Projects selected as part of the Quantum Leap program focus on developing cutting-edge technologies with the potential to significantly advance the R&D activities of CQDM’s pharmaceutical members. Quantum Leap projects are executed in close collaboration and with the expert support and funds of pharmaceutical members.
###### Funding Amount and/or Duration CQDM will review applications for its pharma-led funding program for drug discovery research subject to the following: * Requested funds must range from $500,000 to $1,200,000 for 1 to 3 years. Exceptionally, CQDM may consider applications exceeding the maximum, if appropriate. * CQDM pharmaceutical members must have pledged at least one third (1/3) of the funds required to support the project.
* Applicants are responsible for raising matched funding for the project. When possible, CQDM may offer support to applicants. * CQDM may call on a number of national and international partner organizations potentially interested in co-financing certain projects.
For example, preliminary discussions with CQDM could help maximize contributions from various partners toward launching a drug discovery research project (see below for details on international collaborations). * Applicants with a secured financial commitment from the industry or from a private, semi-private and public organization (either for-profit or non-profit)could be advantaged.
* The funding may consist in a grant or an investment. * A detailed breakdown of requested funding must be provided and will be carefully examined by CQDM. * Applicants who wish to apply for Mitacs funding (available to graduate students and postdoctoral fellows involved in a CQDM project) must fill out the appropriate Mitacs section on the CQDM application form.
Currency: Canadian Dollar (CAD) Agency Deadline (External) Internal approval by the Chair/Director and Dean through https://sfu. kuali. co/ is due to ORS at least 3 business days before the external deadline.
Please allow enough time for Chair/Director and Dean approval according to your unit's requirements. (Please note that this does not concern applications administered by ISA.) Contact Climate Innovation Director of Strategy Deborah Harford (dharford@sfu.
ca) for assistance with funding applications related to climate change research. The Quantum Leap pharma-led funding program for drug discovery research is open to all SMEs and public research institutions in Canada. Budget structures can vary depending on each project.
You must contact CQDM to confirm eligibility before applying. ###### Allowable Expenses **Eligible costs of the pharma-led funding program for drug discovery research** * Salary and benefits of research personnel required to execute the project (technical/professional assistants, post-doctoral fellows, and students). * Material and laboratory supplies including services provided by third-party suppliers required to execute the project.
* Equipment or facilities (purchase or rental). * Wages of the principal investigator (PI) and co-investigators from universities and their affiliated research centers. ###### Application Process * Fill out theQuantum Leap pharma-led funding program for drug discovery research application form Call for proposals are open year-round for Quantum Leap projects.
The deadline to participate in the next selection round is February 15, 2024. Contact Jesse Paterson for more information atjpaterson@cqdm. org ###### For More Information ###### Other Useful Information Questions about this opportunity can be sent to CQDM at appliquez-apply@cqdm.
org SFU Signature Sheet and Full Application are due to ORS three (3) business days before the application deadline.
According to the current listing, eligibility includes: Open to all SMEs and public research institutions in Canada. Applicants are responsible for raising matched funding for the project, with CQDM pharmaceutical members pledging at least one-third of the required funds. Confirm the full requirements in the official notice before applying.
The current listing shows $500,000 to $1,200,000 for 1 to 3 years (with potential for larger awards). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Quantum Leap pharma-led funding program for drug discovery research is funded by Quebec Consortium for Drug Discovery (CQDM). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleCDC-RFA-EH-27-0074 posted as a forecast September 22, 2026: 6 expected awards at $750,000 to $900,000. That is flat funding against the expiring cycle — and the only proven way in is the consortium model Arizona used to bring three states under one award.
Read articleDARPA's DIAL program already had AI rediscover the Kalman filter and wavelets from scratch. SPEED DIAL (DPA26TZ05-DV003) funds the unglamorous next step: turning algorithm discovery into a tool that plugs into MATLAB, Simulink, and COMSOL. Up to $750,000 base plus a $1.25 million option, Direct to Phase II only, with a three-accomplishment feasibility gate and a mandatory university partner. Here is the milestone schedule, the interpretability requirement, and who is actually eligible.
Read article